⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTOR News
Citius Oncology, Inc. Common Stock
Form 8-K
sec.gov
CTOR
CTXR
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTOR
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
prnewswire.com
CTXR
CTOR
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTOR
CTXR
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
prnewswire.com
CTXR
CTOR
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTOR
CTXR
Form 8-K
sec.gov
CTXR
CTOR